AELIS
XPAR
Market cap11mUSD
Nov 20, Last price
0.77EUR
1D
-3.50%
1Q
-27.17%
IPO
-93.57%
Name
Aelis Farma SA
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Aelis Farma S.A., a French biotechnology company founded in 2013 and headquartered in Bordeaux, is dedicated to the discovery and development of treatments for brain-related illnesses. The firm's research pipeline primarily focuses on signaling-specific inhibitors that target CB1 receptors. Its leading investigational drug, AEF0117, is currently advancing through Phase 2b clinical trials, designed to alleviate the harmful impacts of excessive cannabis consumption. Furthermore, AEF0217, another key drug candidate, has successfully completed Phase 1 clinical trials, with the goal of addressing cognitive impairments linked to Down syndrome and other similar conditions.
Key people
Pier Piazza
Chief Executive Officer, Director · since 2023
Sandy Fabre
Co-Founder, Head - Discovery and IP Leader
Marie Line Lafevre
Head - Finance
Stephanie Monlezun
Co-Founder, Chief Operating Officer
Lea Floquet
Head - Legal
Aurelie Boucard
Head - Preclinical Development
Corinne Chaimbault
Head - Pharmaceutical Development
Arsene Guekam
Chief Corporate Development Officer
Helle Mengel
Head - Clinical Development
M. Brahim Guetarni
Director, Representative of Nouvelle-Aquitaine Region · since 2021
Karina Hansen
Independent Director · since 2022
Independent Director · since 2022
Independent Chairman of the Board · since 2020
Independent Director · since 2022
Headquarters & legal address
2 RUE ROBERT ESCARPIT
IECB
PESSAC 33600
FR
IECB
PESSAC 33600
FR
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||